Premium
Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod
Author(s) -
Seeberger Josef,
Daoud Saleh,
Pammer Johannes
Publication year - 2003
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.2003.01955.x
Subject(s) - imiquimod , medicine , dermatology , cutaneous leishmaniasis , leishmaniasis , placebo , immunology , pathology , alternative medicine
Background Treatment of cutaneous leishmaniasis can be painful and protracted and cosmetic results are often unsatisfying. The immune modulator imiquimod has been reported to be suitable for the treatment of a variety of infectious skin diseases and neoplasias. Objective We investigated the efficacy of topical application of imiquimod in the treatment of old world leishmaniasis in a placebo‐controlled prospective study. Methods Twelve patients were treated with imiquimod cream using a standard protocol, i.e. topical application three times a week, and a further three served as control group. Results Lesions of cutaneous leishmaniasis regressed within the first 2–4 weeks in 10 of the 12 patients, whereas in two patients no change was observed. However, after 8 weeks all lesions showed progression. Conclusion Our results thus demonstrate that topical application of imiquimod alone is ineffective in treating old world cutaneous leishmaniasis. Further studies are required to demonstrate a possible benefit of imiquimod in combination with other, preferably orally administered medicines.